The Priority Review and Phase 3 data publication de-risk cemdisiran's approval path. Monitor the November 2026 PDUFA date and any AdCom meeting. If approved, cemdisiran could add a new growth driver to Regeneron's pipeline beyond Eylea and Dupixent. The stock may see positive momentum ahead of the decision.
REGN drugs
REGN drug pipeline →- ● Otarmeni 3/10 Approved (accelerated approval) · BLA filing 2026
- ▲ Cemdisiran 6/10 Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review)
- ▲ Dupixent 4/10 Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
- ● Evkeeza 4/10 Approved
- ● EYLEA HD 4/10 Approved
- 12 more · All REGN drugs, catalysts & trials →
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 22 $612.50entry
- T+1 · 5mo ago +0.90%α +2.36% · $618.03
- T+5 · 5mo ago +3.33%α +5.40% · $632.90
- T+20 · 4mo ago +10.48%α +10.63% · $676.69
- T+60 · 2mo ago +26.39%α +24.64% · $774.11
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Regeneron announced FDA and EMA acceptance of regulatory applications for cemdisiran, an investigational siRNA therapy for generalized myasthenia gravis (gMG). The FDA granted Priority Review with a target action date in November 2026, and the EMA decision is expected in H2 2027. This is a significant pipeline catalyst for Regeneron, as cemdisiran could become the first siRNA approved for gMG with a convenient subcutaneous dosing schedule four times a year.
Key Facts
- FDA accepted NDA for cemdisiran under Priority Review; target action date November 2026.
- EMA accepted regulatory application; decision anticipated H2 2027.
- Cemdisiran is an investigational siRNA targeting C5 for anti-AChR antibody-positive gMG.
- Phase 3 NIMBLE trial data published in The Lancet and presented at AAN 2026.
- Subcutaneous dosing every 12 weeks (four times a year), potential convenience advantage.
- Regeneron is solely responsible for development, manufacturing, and commercialization via Alnylam licensing agreement.
- Priority Review Voucher used for the NDA submission.
- gMG affects ~85,000 people in the U.S.; estimated 150-200 per million globally.
Financial Impact
Cemdisiran targets a large gMG market (~85,000 U.S. patients) with potential to become first siRNA approved for the indication. No revenue or deal value disclosed.
Risk Factors
- Regulatory risk: FDA may issue a Complete Response Letter (CRL) despite Priority Review.
- Competition: existing gMG therapies (e.g., Soliris, Vyvgart) and other pipeline candidates could limit market share.
- Commercialization risk: pricing, reimbursement, and physician adoption uncertainties.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3315167 |
Track record
53 reports on REGN
10 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 16 of 20 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
- Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
- Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers